Topical Collection "Sphingolipid Signaling in Health and Disease"

Dear colleagues,

Sphingolipids have long been known as important structural components of biological membranes. This view has drastically changed after groundbreaking discoveries in the early 1990s, which showed that certain sphingolipid subspecies are bioactive and are able to induce signal transduction and regulate fundamental cellular responses such as cell proliferation and survival, differentiation, apoptosis, and migration. Evidence is now increasing that the disregulation of sphingolipid signaling contributes to the pathogenesis of multiple diseases, including inflammation, pain, cancer, diabetes, cardiovascular dysfunction, organ fibrosis, and various neurodegenerative diseases. Nevertheless, the exact molecular mechanisms used by sphingolipids to mediate the cellular effects are still not completely understood. Also, the regulation of those enzymes that catalyze the generation and interconversion of sphingolipids, although being cloned and known for decades, are not well described.

This Special Issue is dedicated to shedding light on the molecular mechanisms used by bioactive sphingolipids, including sphingosine, ceramides, glycosphingolipids, and phosphorylated sphingoids, and to better characterize their involvement in physiological, pathophysiological, and pathological conditions. Furthermore, advances in the development of new drugs and strategies to manipulate sphingolipid-regulating enzymes and receptors for therapeutic applications are welcome.

Prof. Andrea Huwiler
Guest Editor

In collaboration with Sphingolipid Club, 300 CHF discount would be applied for the submissions in the Topical Collection "Sphingolipid Signaling in Health and Disease" from officially registered Sphingolipid Club members. Please notice that if your institute is participating in the MDPI Institutional Open Access Program (IOAP,, one discount from the two alternatives would be applied.

Currently an article processing charge (APC) of 1800 CHF (Swiss Francs) applies to papers accepted after peer review. See the real-time update here: